JP2024542212A - 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート - Google Patents

治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート Download PDF

Info

Publication number
JP2024542212A
JP2024542212A JP2024529599A JP2024529599A JP2024542212A JP 2024542212 A JP2024542212 A JP 2024542212A JP 2024529599 A JP2024529599 A JP 2024529599A JP 2024529599 A JP2024529599 A JP 2024529599A JP 2024542212 A JP2024542212 A JP 2024542212A
Authority
JP
Japan
Prior art keywords
pharma
compound
acceptable salt
ceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542212A5 (enExample
Inventor
ジョン マグワイア，ロバート
マリー チェンゲリー，ヨハンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybrexa 4 Inc
Original Assignee
Cybrexa 4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 4 Inc filed Critical Cybrexa 4 Inc
Publication of JP2024542212A publication Critical patent/JP2024542212A/ja
Publication of JP2024542212A5 publication Critical patent/JP2024542212A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024529599A 2021-11-17 2022-11-16 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート Pending JP2024542212A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280409P 2021-11-17 2021-11-17
US63/280,409 2021-11-17
PCT/US2022/079973 WO2023091957A1 (en) 2021-11-17 2022-11-16 Peptide conjugates of peptidic tubulin inhibitors as therapeutics

Publications (2)

Publication Number Publication Date
JP2024542212A true JP2024542212A (ja) 2024-11-13
JP2024542212A5 JP2024542212A5 (enExample) 2025-11-25

Family

ID=84799580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529599A Pending JP2024542212A (ja) 2021-11-17 2022-11-16 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート

Country Status (14)

Country Link
US (1) US20230416331A1 (enExample)
EP (1) EP4433095A1 (enExample)
JP (1) JP2024542212A (enExample)
KR (1) KR20240130157A (enExample)
CN (1) CN118574642A (enExample)
AU (1) AU2022390891A1 (enExample)
CA (1) CA3243300A1 (enExample)
CL (1) CL2024001486A1 (enExample)
CO (1) CO2024007413A2 (enExample)
IL (1) IL312884A (enExample)
MX (1) MX2024005938A (enExample)
PE (1) PE20242180A1 (enExample)
TW (1) TW202330015A (enExample)
WO (1) WO2023091957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399267T3 (es) * 2005-01-18 2013-03-27 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno
JP6262768B2 (ja) * 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
KR20220052918A (ko) * 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) * 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Also Published As

Publication number Publication date
CN118574642A (zh) 2024-08-30
EP4433095A1 (en) 2024-09-25
KR20240130157A (ko) 2024-08-28
CL2024001486A1 (es) 2024-11-29
AU2022390891A1 (en) 2024-06-06
PE20242180A1 (es) 2024-11-07
TW202330015A (zh) 2023-08-01
US20230416331A1 (en) 2023-12-28
IL312884A (en) 2024-07-01
CA3243300A1 (en) 2023-05-25
CO2024007413A2 (es) 2024-11-18
WO2023091957A1 (en) 2023-05-25
MX2024005938A (es) 2024-08-14

Similar Documents

Publication Publication Date Title
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TWI820077B (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
JP2022541749A5 (enExample)
JP7675060B2 (ja) 治療薬としての微小管標的化剤のペプチドコンジュゲート
CN118878461A (zh) Pd-1/pd-l1抑制剂
CN111801331A (zh) 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
EA051761B1 (ru) Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств
WO2022155172A1 (en) Peptide conjugates of therapeutics
EA051826B1 (ru) Пептидные конъюгаты цитотоксинов в качестве терапевтических средств
HK40094758A (zh) 新型谷氨醯胺类似物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114